ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2018

Abstract Number: 1290

Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study

Silvia Rollefstad1, Till Uhlig2,3, Lars Fridtjof Karoliussen3, Hilde B. Hammer4 and Anne Grete Semb5, 1Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2University of Oslo, Oslo, Norway, 3Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, 5Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: Atherosclerosis, Cardiovascular disease, gout, inflammation and lipids

Session Information

Date: Monday, October 22, 2018

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Systemic inflammation and atherosclerosis in patients with gout. Results from the NOR-Gout study

Background/Purpose: The association between gout and cardiovascular disease (CVD) is well known, whereas mechanisms behind this association are poorly understood. This study aimed to evaluate factors associated with asymptomatic carotid atherosclerosis in patients with gout.

Methods: In this prospective study patients with crystal-proven gout were included after a recent disease flare, if the serum urate level was >360 µmol/L (>6 mg/dl). We analysed baseline data in patients without established CVD who were referred to a CVD risk evaluation, including ultrasound of the carotid arteries, blood pressure measurement and laboratory tests. Carotid atherosclerotic plaques were defined in the longitudinal view as protrusions into the lumen of ≥1.5 mm or at least 2 times the adjacent intima-media thickness according to the Mannheim criteria.

Results: Of the 79 gout patients included, approximately 10% were females, and mean (SD) age was 52.1±13.1 years. 32 (40.5%) had carotid plaques (Table). Only 9.3% were current smokers, while mean (SD) body mass index was high (29.1±4.7 kg/m2). Lipids were in the normal range, with a mean (SD) total cholesterol at 5.3±1.09 mmol/L and low density lipoprotein cholesterol 3.12±0.95 mmol/L. Systolic blood pressure was in the normal range 134.0±15.1 mmHg, although 29.1% of the patients were treated with antihypertensive agents.

In univariate analyses, higher age, hypertension and higher erythrocyte sedimentation rate (as a marker of systemic inflammation) were significantly associated with the presence of carotid plaques (p=0.01 and p=0.04, respectively) (Figure). However, there were no statistically significant relations after adjusting for age, a strong predictor for development of atherosclerosis. Serum urate levels or disease duration were not associated with carotid plaques (p=0.27 and p=0.44, respectively).

Conclusion: Our results indicate an association between systemic inflammation and atherosclerosis in patients with gout. To be able to efficiently prevent CVD in this patient group, prospective studies with larger sample sizes are needed to elucidate the mechanisms behind the increased risk of CVD in gout patients. 

Figure. Association between inflammation and atherosclerosis

     

Table. Patients characteristics

All

+carotid plaque

÷carotid plaque

p-value

Number n (%)

79 (100.0)

32 (40.5)

47 (59.5)

–

Age (years) mean±SD

52.1±13.1

60.0±10.4

46.7±12.1

<0.0001

Sex male/female n (%)

72/7 (91.1)/(8.9)

28/4 (87.5)/(12.5)

44/3 (93.6)/(6.4)

0.43

Disease duration

(median IQR)

6.0 (3.0-12.0)

6.0 (3.8-14.3)

5.0 (2.0-10.0)

0.44

CV risk factors

Smoking n (%)

7 (9.3)

2 (2.7)

5 (6.7)

0.69

BMI mean±SD

29.1±4.7

28.5±4.2

29.5±5.0

0.35

TC (mmol/L) mean±SD

5.3±1.09

5.21±1.18

5.39±1.02

0.48

LDL-c (mmol/L) mean±SD

3.12±0.95

3.24±1.07

3.04±0.84

0.41

BP systolic (mm Hg) mean±SD

134.0±15.1

138.0±16.2

131.3±13.9

0.06

BP diastolic (mm Hg) mean±SD

82.8±8.0

83.6±6.9

82.3±8.8

0.46

Co-morbidities n (%)

Hypertension

36 (45.6)

21 (26.6)

15 (19.0)

0.01

Diabetes

4 (5.1)

3 (3.8)

1 (1.3)

0.30

Biomarkers mean±SD

S-urate (µmol/L)

ESR (mm/h)

495.6±84.0

12.9±13.9

481.8±97.5

17.3±17.6

504.9±73.2

9.8±9.7

0.27

0.04

CRP (mg/L) median (IQR)  

3.5 (2.0-7.8)

5.0 (2.0-13.5)

3.0 (1.0-6.0)

0.09

               


Disclosure: S. Rollefstad, None; T. Uhlig, Biogen, 5,Bristol-Myers Squibb, 5,Eli Lilly and Co., 5,Janssen, 5,Merck & Co., 5,Novartis, 5,Roche, 5; L. F. Karoliussen, None; H. B. Hammer, None; A. G. Semb, None.

To cite this abstract in AMA style:

Rollefstad S, Uhlig T, Karoliussen LF, Hammer HB, Semb AG. Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/systemic-inflammation-and-atherosclerosis-in-patients-with-gout-results-from-the-nor-gout-study/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-inflammation-and-atherosclerosis-in-patients-with-gout-results-from-the-nor-gout-study/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology